Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-K (Annual Report)
Period Ended: June 27, 2009 (52-week fiscal year)
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an intelligent robotic radiosurgery system used to treat solid tumors anywhere in the body. As of June 30, 2009, 176 systems were installed globally (115 in the Americas, 43 in Asia, 18 in Europe). The company also offers shared ownership programs and multiyear service plans.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 | Fiscal 2007 |
|---|---|---|---|
| Net Revenue | $233.6 million | $210.4 million | $140.5 million |
| Gross Profit | $115.3 million | $107.0 million | $80.0 million |
| Gross Margin | 49.4% | 50.8% | 57.0% |
| Operating Loss | ($2.4) million | ($0.9) million | ($8.5) million |
| Net Income | $0.6 million | $5.4 million | ($5.6) million |
| Cash and Cash Equivalents | $36.8 million | $36.9 million | $204.8 million |
| Total Assets | $274.4 million | $295.0 million | $332.1 million |
| Working Capital | $80.1 million | $87.7 million | $148.5 million |
| Backlog (Total) | $555.9 million | $647.0 million | N/A |
Note: The company reported a net income of $609,000 for 2009, a significant decrease from $5.4 million in 2008. Operating cash flow was negative $8.0 million in 2009 compared to negative $18.0 million in 2008.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 11% year-over-year to $233.6 million, driven by a 4.5% increase in product revenue and a 71% increase in service revenue. However, shared ownership program revenue declined 64% due to the sale of systems previously under the program.
- Profitability: While the company returned to profitability in 2009 (net income of $0.6 million), it was significantly lower than the $5.4 million net income in 2008. Gross margin decreased slightly to 49.4% from 50.8% due to a higher mix of lower-margin service revenue.
- Operating Expenses: Total operating expenses increased to $117.7 million from $107.9 million. Increases were driven by severance charges ($2.4 million in G&A, $0.5 million in S&M, $0.3 million in R&D) and higher legal/audit fees related to an inventory investigation.
- Inventory: Inventory levels increased by $5.9 million to $28.9 million, reflecting business volume growth and service inventory requirements. The company recorded a $2.7 million write-down of inventory in 2009.
- Investments: The company reclassified $22.4 million of Auction Rate Securities (ARS) from available-for-sale to trading securities due to failed auctions, resulting in a $1.7 million unrealized loss recorded in other income/expense.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management believes current cash resources are sufficient for at least the next 12 months. The company anticipates revenue from legacy Platinum service plans will decline to approximately $24 million in 2010 and $4 million in 2011 as upgrade obligations are fulfilled.
- Backlog Reporting Change: Beginning in fiscal 2010, the company will no longer disclose "contingent" backlog, reporting only non-contingent orders to enhance financial modeling utility.
- Legal Proceedings: Following the fiscal year end, three securities class action lawsuits and one shareholder derivative lawsuit were filed alleging false or misleading statements regarding operations. Additionally, a trade secret lawsuit was filed by Best Medical International, Inc.
- Regulatory Risks: The company faces risks related to the Stark Law (physician self-referral) and Anti-Kickback Statute, particularly regarding physician-owned entities and shared ownership programs. New regulations effective October 1, 2009, may require restructuring of certain customer arrangements.
- Internal Controls: The company previously reported material weaknesses in internal controls regarding revenue recognition and inventory handling. Management concluded these weaknesses were remediated as of June 30, 2009, and received an unqualified opinion on internal controls from their auditors.
- Unusual Items: The company incurred $1.7 million in restructuring charges related to a workforce alignment plan reducing headcount by approximately 13% in the U.S. Additionally, $97,000 in loss provisions were recognized for long-term manufacturing contracts.
Key Facts for Investor Verification
- Revenue Recognition Complexity: Verify the timing of revenue recognition for legacy "Platinum" service plans, which requires deferral until all upgrade obligations are met. Approximately $60 million of revenue was recognized in 2009 from these plans.
- Inventory Valuation: Confirm the adequacy of the $2.7 million inventory write-down and the $484,000 allowance for doubtful accounts, given the inventory investigation mentioned in the filing.
- ARS Liquidity: Assess the impact of the $22.4 million in Auction Rate Securities (ARS) that failed at auction. While a put option with UBS provides a potential exit at par value by June 2010, liquidity remains constrained.
- Backlog Conversion: Monitor the conversion rate of the $555.9 million backlog into recognized revenue, noting the company's decision to stop reporting contingent backlog in future periods.
- Legal Exposure: Track the status of the post-filing securities class actions and the trade secret lawsuit, as these could result in significant, currently unquantified liabilities.